NEW YORK , Nov. 28, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centessa Pharmaceuticals plc.
Shareholders who purchased shares of CNTA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/centessa-loss-submission-form/?id=33942&from=4
CLASS PERIOD: This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
DEADLINE: November 28, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/centessa-loss-submission-form/?id=33942&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CNTA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 28, 2022. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-centessa-pharmaceuticals-plc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-november-28-2022--nasdaq-cnta-301685820.html
SOURCE The Gross Law Firm
